Artrya joins the All Ordinaries in March 2026 rebalance
Artrya Limited (ASX: AYA) has been added to the S&P/ASX All Ordinaries Index, effective prior to the open of trading on Monday, 23 March 2026. The Artrya All Ordinaries Index Addition follows S&P Dow Jones Indices’ quarterly rebalance, which saw 43 companies added to Australia’s broadest equity benchmark. Artrya is an AI-powered cardiac diagnostics company commercialising technology designed to analyse coronary artery disease from medical imaging.
The inclusion marks a milestone for the Perth-based healthcare technology firm, signalling it has met the minimum market capitalisation and liquidity thresholds required for index membership. Artrya joins the All Ordinaries alongside 42 other additions, including fellow healthcare innovator Saluda Medical and biotechnology firm EchoIQ.
When big ASX news breaks, our subscribers know first
What is the All Ordinaries Index?
The All Ordinaries is Australia’s oldest and broadest share market index, comprising approximately 500 of the largest ASX-listed companies by market capitalisation. It serves as a comprehensive barometer of the Australian equity market, encompassing sectors from financials and resources to healthcare and technology.
Unlike the narrower S&P/ASX 200, which tracks the top 200 companies, the All Ordinaries provides exposure to a wider universe of mid-cap and emerging large-cap stocks. S&P Dow Jones Indices conducts quarterly reviews to add or remove constituents based on size and liquidity criteria, ensuring the index remains representative of the Australian market.
Key facts about the All Ordinaries:
- Covers approximately 500 ASX-listed companies
- Rebalanced quarterly by S&P Dow Jones Indices
- Australia’s longest-running equity index
- Broader market coverage than the S&P/ASX 200
- Used as a benchmark by fund managers and investors
Index inclusion matters because it positions companies for increased visibility among institutional and retail investors. Companies within the All Ordinaries may attract passive fund flows from index-tracking products, including exchange-traded funds (ETFs) that replicate the index’s composition.
What index inclusion means for Artrya shareholders
The Artrya All Ordinaries Index Addition (ASX: AYA) represents market recognition of the company’s growth trajectory as it commercialises its AI-powered cardiac imaging technology. Meeting the index’s market capitalisation and liquidity thresholds reflects underlying share price performance and trading activity over recent quarters.
For shareholders, index membership carries several potential benefits:
- Broader investor awareness: Inclusion in a major benchmark index increases the company’s profile among institutional investors and fund managers who track the All Ordinaries.
- Passive fund eligibility: Index-tracking funds and ETFs that replicate the All Ordinaries will now hold Artrya shares, potentially providing a stable base of passive holders.
- Enhanced liquidity: Index membership can support improved trading liquidity as more investors gain exposure to the stock through diversified portfolios.
- Reduced volatility: A more diversified investor base, including passive holders who maintain positions through market cycles, may contribute to share price stability over time.
Meeting index thresholds demonstrates the company has achieved sufficient scale and market depth to warrant inclusion in Australia’s broadest equity benchmark. This positions Artrya alongside established healthcare companies and emerging technology firms within the index’s approximately 500 constituents.
The next major ASX story will hit our subscribers first
Looking ahead
The inclusion takes effect from 23 March 2026, with changes implemented prior to the market open. Artrya joins alongside 42 other companies being added in this quarterly rebalance, reflecting S&P Dow Jones Indices’ ongoing review of market capitalisation and liquidity metrics across the ASX.
This milestone provides a foundation as the company continues its commercialisation journey in the cardiac diagnostics sector. Index membership may support the company’s visibility among investors as it advances its AI-powered technology platform through clinical validation and market adoption phases.
Want the Next Healthcare Breakthrough in Your Inbox?
Join 20,000+ investors receiving FREE breaking ASX healthcare news within minutes of release, complete with expert analysis. Big News Blast delivers market-moving announcements the moment they drop. Click the “Free Alerts” button to stay ahead on healthcare breakthroughs like Artrya’s All Ordinaries inclusion.